Long-term disease control with sunitinib in a patient with metastatic pancreatic neuroendocrine tumor (NET) associated with Von Hippel-Lindau syndrome (VHL).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Non-Interventional Management of Advanced Pancreatic Neuroendocrine Neoplasms in Patients with von Hippel-Lindau Disease.Cancers · 2023
   Review
2. Von Hippel-Lindau Disease: Current Challenges and Future Prospects.OncoTargets and therapy · 2020
   Review
3. The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel-Lindau Disease: A Retrospective Study of 32 Patients.Frontiers in oncology · 2019
   Article
4. An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.Internal medicine (Tokyo, Japan) · 2018
   Article
5. A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease.Cancer biology & therapy · 2018
   Article
6. Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease.Nature reviews. Clinical oncology · 2016
   Review
7. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.Familial cancer · 2015
   Article
8. Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib.Therapeutic advances in gastroenterology · 2013
   Article
9. A differential diagnosis of inherited endocrine tumors and their tumor counterparts.Clinics (Sao Paulo, Brazil) · 2013
   Review
10. Proteostasis modulators prolong missense VHL protein activity and halt tumor progression.Cell reports · 2013
    Article

Corrections and comments

• Comment on
  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.2010

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as